Facing setbacks for months and an activist attack, Catalyst Biosciences prepares to call it quits
After downsizing for several months, Catalyst Biosciences is getting ready to tap out.
The San Francisco biotech announced Wednesday that it would be liquidating and distributing cash back to shareholders, with total proceeds expected to reach $65 million. Catalyst intends to return the money “as soon as practicable,” the company said, as it has ceased all R&D activities, CEO Nassim Usman said in a statement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.